Psylo

Psylo

Psychedelic medicine to treat mental illness

View website

Challenge

Sustainable Development Goals

Company-hero-image

Psylo

Psylo

Psychedelic medicine to treat mental illness

View website

Challenge

Sustainable Development Goals

Company-hero-image

Founders

Joshua Ismin

Co-Founder and CEO

Joshua holds an MBA and BSBA from Washington University in St Louis. Josh is a repeat founder who has launched APAC operations for a number of tech startups, including The Video Network, which he co-founded and sold to a NASDAQ listed company. He is an active investor with a focus on alt-protein and biotech.

01

02

03

04

05

Founders

Dr Sam Banister

Co-Founder and CSO

Dr Sam Banister has extensive small molecule drug development experience within academia and the private sector. He holds his PhD from University of Sydney and completed a Post-doctorate at Stanford University. At Stanford, Dr Banister developed clinical candidates for the treatment of ALS and related neurological disorders, acquired by Tranquis Therapeutics, Inc. He has published 85+ peer-reviewed scientific articles and is an inventor on several patents (2630 citations, H-index 29).

01

02

03

04

05

Founders

01

02

03

04

05

Founders

01

02

03

04

05

Founders

01

02

03

04

05

Joshua Ismin

Co-Founder and CEO

Joshua holds an MBA and BSBA from Washington University in St Louis. Josh is a repeat founder who has launched APAC operations for a number of tech startups, including The Video Network, which he co-founded and sold to a NASDAQ listed company. He is an active investor with a focus on alt-protein and biotech.

01

02

03

04

05

Founders

Dr Sam Banister

Co-Founder and CSO

Dr Sam Banister has extensive small molecule drug development experience within academia and the private sector. He holds his PhD from University of Sydney and completed a Post-doctorate at Stanford University. At Stanford, Dr Banister developed clinical candidates for the treatment of ALS and related neurological disorders, acquired by Tranquis Therapeutics, Inc. He has published 85+ peer-reviewed scientific articles and is an inventor on several patents (2630 citations, H-index 29).

01

02

03

04

05

Founders

01

02

03

04

05

Founders

01

02

03

04

05

Founders

01

02

03

04

05

Founders

Why it matters

Dawn of a new era of psychedelic derived therapeutic treatments.

2 in 5 adults deal with a chronic mental illness each year, and 44% of Australians experience a mental disorder during their lifetime. As a treatment for depression, SSRI antidepressants are only 20% more effective than a placebo, and come with a wide variety of side effects. We are at the dawn of a new era of psychedelic derived therapeutic treatments. Extensive research is needed to uncover ways we might harness the power these substances have to offer.

How it works

Iterating on what exists in nature to discover new treatments for mental illness.

Psylo is a drug development company focused on next generation psychedelics; we use computational chemistry to optimise the pharmacology of compounds inspired by psychedelics that exist in nature. Our goal is to make broadly accessible medicines as improved treatments to currently available SSRI medications, using psychedelic molecules as the starting point.

Why it matters

Dawn of a new era of psychedelic derived therapeutic treatments.

2 in 5 adults deal with a chronic mental illness each year, and 44% of Australians experience a mental disorder during their lifetime. As a treatment for depression, SSRI antidepressants are only 20% more effective than a placebo, and come with a wide variety of side effects. We are at the dawn of a new era of psychedelic derived therapeutic treatments. Extensive research is needed to uncover ways we might harness the power these substances have to offer.

How it works

Iterating on what exists in nature to discover new treatments for mental illness.

Psylo is a drug development company focused on next generation psychedelics; we use computational chemistry to optimise the pharmacology of compounds inspired by psychedelics that exist in nature. Our goal is to make broadly accessible medicines as improved treatments to currently available SSRI medications, using psychedelic molecules as the starting point.

The WOW factor

The Wow Factor

Psylo has 5 compounds in their development pipeline. These non-hallucinogenic psychiatric therapies have the potential to be more effective than traditional medicine in treating mental illnesses.

The WOW factor

The Wow Factor

Psylo has 5 compounds in their development pipeline. These non-hallucinogenic psychiatric therapies have the potential to be more effective than traditional medicine in treating mental illnesses.

Investment Team

Gabrielle Munzer

Partner

Investment Team

Gabrielle Munzer

Partner

"

Australian startup Psylo advances depression treatment with Japanese pharma firm Daiichi Sankyo

BioSpectrum Asia

"
"

Psychedelic biotech startup Psylo raises $5 million Seed round

Startup Daily

"
"

Main Sequence Ventures, Lionheart Ventures back Aussie psychedelics start-up Psylo

AFR

"
"

Australian startup Psylo advances depression treatment with Japanese pharma firm Daiichi Sankyo

BioSpectrum Asia

"
"

Psychedelic biotech startup Psylo raises $5 million Seed round

Startup Daily

"
"

Main Sequence Ventures, Lionheart Ventures back Aussie psychedelics start-up Psylo

AFR

"

Co-investors

No items found.

Related Companies

HomePortfolioChallengesPitchJobs
AboutTeamNewsContact UsInvest
© All rights reserved.
Legal notice & disclaimerPrivacy Policycopyright noticeaccessibility